Physician profile
Stephen E Hemperly
NPI 1013277045
$8,719.70
in general payments reported to CMS, 2019-2025
28 companies · $2,251 in 2025
The $2,251 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,289 · 2020: $361 · 2021: $422 · 2022: $499 · 2023: $1,246 · 2024: $2,653 · 2025: $2,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,680 · Education: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,679.82 |
| Education | $469.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,656.77 | 2019-2025 | |
| Janssen Biotech, INC. | $1,245.77 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $704.76 | 2019-2025 | |
| Incyte Corporation | $668.60 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $642.93 | 2019-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $623.46 | 2021-2025 | Libtayo, Dupixent |
| Sun Pharmaceutical Industries INC. | $549.81 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $478.82 | 2023-2025 | Sotyktu |
| Amgen INC. | $337.51 | 2019-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $311.75 | 2023-2024 | Vtama |
| Pfizer INC. | $277.64 | 2019-2025 | |
| Genzyme Corporation | $246.22 | 2019-2025 | |
| Ucb, INC. | $213.10 | 2021-2025 | Bimzelx |
| Genentech USA, INC. | $151.96 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $132.04 | 2023-2025 | Zoryve |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $101.94 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $87.57 | 2019-2025 | Nemluvio |
| Stemline Therapeutics INC. | $86.05 | 2019 | |
| Organon LLC | $36.16 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $22.97 | 2024 | Ycanth |
| Celgene Corporation | $21.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.74 | 2025 | Spevigo |
| Merck Sharp & Dohme LLC | $19.70 | 2019 | |
| Allergan, INC. | $19.69 | 2020 | |
| Vyne Pharmaceuticals INC. | $17.59 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $17.27 | 2019 | |
| Strata Skin Sciences, INC. | $15.63 | 2022 | |
| Sientra, INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Hemperly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.